Grifols launches AlphaID at home, enabling U.S. consumers to self-screen for genetic COPD
Grifols announced it has launched its AlphaID At Home Genetic Health Risk Service (AlphaID At Home), the free direct-to-consumer program in the U.S., to screen for the genetic risk of alpha1-antitrypsin deficiency (alpha-1).
With AlphaID At Home people can collect a small saliva sample without needing to visit a healthcare professional to learn their risk of developing lung and/or liver disease linked to alpha-1.
AlphaID At Home is now available to order in the U.S. without cost through a secure HIPAA-compliant online portal.
Once the at-home screening kit arrives, individuals simply collect their saliva sample and send it to a CLIA-certified lab for processing. After a few weeks, they can access their genetic results on the secure online portal. Individuals are encouraged to share the results with their doctor, as only a healthcare provider can make a diagnosis of alpha-1.
Cleared by the U.S. Food and Drug Administration (FDA) in November 2022 for direct-to-consumer use, AlphaID At Home screens for the 14 most prevalently reported genetic mutations associated with alpha-1 – the most of any test of its kind – including the S, Z, F, I alleles, as well as rare and null alleles.
To order a free AlphaID At Home kit, please visit www.alphaidathome.com.
To learn more about genetic COPD, please visit www.geneticCOPDtest.com.
To learn more about alpha-1, please visit the Alpha-1 Foundation at www.alpha1.org.
